Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice

PLoS One. 2015 Aug 27;10(8):e0136873. doi: 10.1371/journal.pone.0136873. eCollection 2015.

Abstract

Activation of TGR5 via bile acids or bile acid analogs leads to the release of glucagon-like peptide-1 (GLP-1) from intestine, increases energy expenditure in brown adipose tissue, and increases gallbladder filling with bile. Here, we present compound 18, a non-bile acid agonist of TGR5 that demonstrates robust GLP-1 secretion in a mouse enteroendocrine cell line yet weak GLP-1 secretion in a human enteroendocrine cell line. Acute administration of compound 18 to mice increased GLP-1 and peptide YY (PYY) secretion, leading to a lowering of the glucose excursion in an oral glucose tolerance test (OGTT), while chronic administration led to weight loss. In addition, compound 18 showed a dose-dependent increase in gallbladder filling. Lastly, compound 18 failed to show similar pharmacological effects on GLP-1, PYY, and gallbladder filling in Tgr5 knockout mice. Together, these results demonstrate that compound 18 is a mouse-selective TGR5 agonist that induces GLP-1 and PYY secretion, and lowers the glucose excursion in an OGTT, but only at doses that simultaneously induce gallbladder filling. Overall, these data highlight the benefits and potential risks of using TGR5 agonists to treat diabetes and metabolic diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Evaluation, Preclinical / methods
  • Gallbladder / drug effects*
  • Gallbladder / physiopathology
  • Gene Expression Regulation
  • Glucagon-Like Peptide 1 / metabolism
  • Glucose Tolerance Test
  • HEK293 Cells
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / pharmacology*
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Peptide YY / metabolism
  • Receptors, G-Protein-Coupled / agonists*
  • Receptors, G-Protein-Coupled / genetics
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology
  • Weight Loss / drug effects

Substances

  • GPBAR1 protein, human
  • Gpbar1 protein, mouse
  • Hypoglycemic Agents
  • Receptors, G-Protein-Coupled
  • Small Molecule Libraries
  • Peptide YY
  • Glucagon-Like Peptide 1

Grants and funding

Eli Lilly and Company provided support in the form of salaries for authors DAB, XR, CCC, AMS, TEF, CD, SGS, CM, CSS, YX, TC, and MDM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.